ALMED Medicrea International

Etude de l'AG du 08/11/2017

La société soumet à l'approbation des actionnaires trois autorisations : une opération d'émission d'options de souscription ou d'achat (résolution 1), une attribution d'actions gratuites (résolution 2) et une émission réservée aux salariés (résolution 3).

La société a désiré augmenter le plafond de l'ensemble des autorisations de 7,5% du "Plafond Global I" défini par l'assemblée générale du 11 mai 2017. Elle justifie ces opérations par le besoin de "continuer à disposer de ce système [de rémunération] pour associer le personnel, notamment la filiale aux Etats-Unis, et les dirigeants de la société et du groupe, au bon développement de celui-ci".

Cependant, le plafond représente des risques dilutifs trop importants. De plus, la société ne communique ni condition de performance, ni plafond pour les dirigeants, ce qui amène Proxinvest à recommander un vote négatif pour les résolutions 1 et 2.

24/10/2017
10 pages
EN

Research Provider

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Read more

Underlying

Health Care - France

Medicrea International SA is a France-based company that specializes in the design and manufacture of medical devices. The Company's product range includes polyaxial implants, impacted lumbar cage, polyaxial spine system, cervical compressive staples, cervical IBD, Lumbar IBD, cervical cage and bone substitutes. The Company has manufacturing facilities in La Rochelle, France. It is operational through such subsidiaries as Medicrea UK, based in the United Kingdom, Medicrea USA, based in the United States and Medicrea Technologies, based in France.

Read more

ResearchPool Subscriptions

Get the most out of your insights

Get in touch